MOA
MOA of cytarabine
Inhibition of DNA polymerase
indications for ibrutinib
MCL, CLL and SLL
BBW for nilotinib
QT prolongation
monitoring for midosaturin
S/S of lung dysfx
warnings for rituximab
PML
MOA of Midosaturin
inhibition of FLT3 receptor signaling inducing cancer cell apoptosis
indication for midosaturin
tx of FLT3 positive AML in conjunction with cytarabine and daunorubicin
BBW for doxorubicin
irreversible myocardial toxicity
monitoring for nilotinib
EKG at baseline and periodically thereafter
warnings for ibrutinib
hemorrhage and Afib
MOA of ibrutinib
inhibition of BTK which blocks malignant B-cell proliferation
indications for cyclophosphamide
NHL, burkitt's and CLL
BBW for vincristine
monitoring for imatinib
LVEF
edema/severe fluid retention and CHF
MOA of gemtuzumab ozogamicin
ADC-CD33 complex which induces cancer cell death
indications for vincristine (both)
Marquibo- Philadelphia chromosome ALL
Oncovin- NHL
BBW of bleomycin
pulmonary fibrosis
warnings for cyclophosphamide
UTI, renal toxicity and pulmonary toxicity
counseling for nilotinib
avoid food when taking and correct hypokalemia or hypomagnesemia prior to administration
MOA of etoposide
inhibition of topoisomerase-II
off-label indication for etoposide
burkitt's lymphoma and multiple myeloma
not a BBW, but what is the drug interaction with etoposide
warfarin (increases INR)
monitoring for doxorubicin
do not exceed lifetime dose and consider adding cardioprotective agent (dexrazoxane)
Write out both R-CHOP and ABVD
R-CHOP is rituximab, cyclophosphamide, doxorubicin, oncovin and prednisone
ABVD is bleomycin, dacarbazine, doxorubicin and vinblastine